EGFR and non-small cell lung carcinoma: In patients with advanced-stage, treatment-refractory NSCLC, SKB264 demonstrated an ORR of 26.0% and an mPFS of 5.3 months in the wild-type EGFR NSCLC group and an ORR of 60.0%, and an mPFS of 11.1 months in the TKI-resistant EGFR-mutant NSCLC group (Figure 1) [128].